Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
Holding MCRB?
Track your performance easily
MCRB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.54 - $2.78
Previous Close$1.1
Volume2.89M
Average Volume (3M)3.78M
Market Cap
$167.62M
Enterprise Value$309.01M
Total Cash (Recent Filing)$71.23M
Total Debt (Recent Filing)$212.63M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 06, 2024EPS Estimate
-$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding151,730,995
10 Day Avg. Volume5,887,006
30 Day Avg. Volume3,784,292
Standard Deviation0.83
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)-1.93
Price to Sales (P/S)413.81
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue826.24
Enterprise Value/Gross Profit2.45
Enterprise Value/Ebitda-3.05
Forecast
1Y Price Target
$4.12Price Target Upside292.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Seres Therapeutics News
PremiumCompany Announcements
Seres Therapeutics’ SER-155 Shows Promising Clinical Results
PremiumCompany Announcements
Seres Therapeutics Releases Financial Statements Ahead of Asset Sale
PremiumCompany Announcements
Seres Therapeutics Unveils Updated Corporate PresentationBulls Say, Bears Say
Bulls Say
EfficacySER-155 significantly lowered bloodstream infections (BSI) vs placebo in cohort 2 of the post-transplant study, which could significantly improve transplant outcomes.
Financial StrategySeres will pay off the debt from Oaktree using capital from VOWST sale, simplifying the capital structure and benefiting Seres in long term.
Product DevelopmentSeres announced development of SER-147 to prevent GI-related infection in patients with metabolic disease, including chronic liver disease.
Bears Say
Cash FlowThe need to raise additional cash has been weighing on the stock, especially as the potential to draw down the $45 mm tranche B under its senior secured debt facility with Oaktree Capital Management looked increasingly uncertain, based on the trend in VOWST net sales.
Cash ReservesThe company ended the quarter with $111.2 mm in unrestricted cash and equivalents, compared to $128 mm at the end of FY23.
Financial Performance1Q24 sales of VOWST were disappointing, flat sequentially at $10.1 mm (-2.9%), based on 642 units of VOWST sold.
---
Ownership Overview
29.63% Insiders
22.81% Mutual Funds
22.34% Other Institutional Investors
25.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MCRB FAQ
What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was $0.54 and its highest was $2.78 in the past 12 months.
What is Seres Therapeutics’s market cap?
Currently, no data Available
When is Seres Therapeutics’s upcoming earnings report date?
Seres Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Seres Therapeutics’s earnings last quarter?
Seres Therapeutics released its earnings results on Aug 13, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.274 by $0.054.
Is Seres Therapeutics overvalued?
According to Wall Street analysts Seres Therapeutics’s price is currently Undervalued.
Does Seres Therapeutics pay dividends?
Seres Therapeutics does not currently pay dividends.
What is Seres Therapeutics’s EPS estimate?
Seres Therapeutics’s EPS estimate is -$0.08.
How many shares outstanding does Seres Therapeutics have?
Seres Therapeutics has 152,381,740 shares outstanding.
What happened to Seres Therapeutics’s price movement after its last earnings report?
Seres Therapeutics reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.274. Following the earnings report the stock price went down -6.742%.
Which hedge fund is a major shareholder of Seres Therapeutics?
Among the largest hedge funds holding Seres Therapeutics’s share is Flagship Pioneering Inc.. It holds Seres Therapeutics’s shares valued at 17M.
---
Seres Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.12 (292.38% Upside)
$4.12 (292.38% Upside)
Blogger Sentiment
Bullish
MCRB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.83%
Trailing 12-Months
Company Description
Seres Therapeutics
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
---
MCRB Earnings Call
Q2 2024
0:00 / 0:00
---
MCRB Stock 12 Month Forecast
Average Price Target
$4.12
▲(292.38% Upside)
Technical Analysis
Fate Therapeutics
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Best Analysts Covering MCRB
1 Year
1 Year Success Rate
11/21 ratings generated profit
1 Year Average Return
+113.70%
reiterated a sell rating last month
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +113.70% per trade.
---